MIA PaCa-2

Description

MIA PaCa-2 is a human pancreatic ductal adenocarcinoma (PDAC) cell line originally established in 1977 from the tumor of a 65‑year‑old Caucasian male. The cells exhibit epithelial-like morphology with abundant cytoplasm, featuring both round and spindle‑shaped adherent cells, as well as loosely attached clusters and some floating cells. The karyotype of MIA PaCa-2 shows hypotriploid with a modal chromosome number of ~61, and demonstrates colony formation in soft agar, consistent with anchorage‑independent tumorigenicity. Genetically, MIA PaCa‑2 harbors homozygous mutations in KRAS (p. G12C), TP53 (p. R248W), and homozygous deletion of CDKN2A/p16^INK4A. It expresses epithelial markers (CK5. 6, AE1/AE3, E‑cadherin), mesenchymal vimentin, and neuroendocrine markers (chromogranin A, synaptophysin), plus SSTR2 and NTR1 receptors. MIA PaCa‑2 retains tumorigenic behavior in xenograft models and is sensitive to L‑asparaginase.

Application

• MIA PaCa-2, is a widely used model for pancreatic cancer research, serves as a crucial tool in elucidating the biology of pancreatic ductal adenocarcinoma, particularly in studies of tumor progression, metastatic potential, and resistance to chemoradiotherapy. Additionally, MIA PaCa-2 is frequently used to analyze the morphological features of PDAC cells and to understand the cellular and molecular changes involved in pancreatic cancer development. This valuable information not only enhances our understanding of pancreatic ductal adenocarcinoma (PDAC) but also paves the way for the discovery of novel diagnostic biomarkers development of targeted therapies, contributing to more personalized and effective treatment strategies for pancreatic cancer patients.